Drug intelligence / Profile preview

SDT-T001

Development stage: Unknown
Lead developer: Cytocraft Biopharmaceutical
Modality: Cell Therapies
Administration: Intravenous

Overview

SDT-T001 is an autologous memory lymphocyte injection developed by Nuowei Technology (Beijing) Co., Ltd. It is a cell therapy designed as an adjuvant treatment for patients with primary hepatocellular carcinoma (HCC) who are at high risk of recurrence following curative surgery. The therapy involves the ex vivo expansion and subsequent re-infusion of the patient's own memory T cells. These cells are intended to provide long-lasting immune surveillance and targeted elimination of residual micrometastatic cancer cells, thereby reducing the likelihood of post-surgical relapse. SDT-T001 is currently being evaluated in a multicenter, randomized, open-label Phase 2 clinical trial in China.

Other names: autologous memory lymphocyte injection

Beyond the preview

Go deeper on SDT-T001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SDT-T001.

Explore the full profile